The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations

Vaccine

Volumn 17, Issue 11-12, 1999, Pages 1416-1424

  Juhasz, Katalin ^a   Whitehead, Stephen S ^a   Boulanger, Corinne A ^a   Firestone, Cai Yen ^a   Collins, Peter L ^a   Murphy, Brian R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Live attenuated vaccine; RSV

Indexed keywords

GLYCINE CLEAVAGE SYSTEM; LIVE VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

AMINO ACID SUBSTITUTION; ARTICLE; ATTENUATION; HEAT SENSITIVITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEQUENCE ANALYSIS; VACCINE PRODUCTION;

AMINO ACID SUBSTITUTION; ANIMALS; CERCOPITHECUS AETHIOPS; HN PROTEIN; HUMANS; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; PHENOTYPE; RESPIRATORY SYNCYTIAL VIRUSES; RNA, VIRAL; SEQUENCE ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPERATURE; TRANSFECTION; VACCINES, ATTENUATED; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0033577312     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00381-8     Document Type: Article

References (22)

1. Collins PL, McIntosh K, Chanock RM. Respiratory syncytial virus. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP et al., editors. Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven, 1996. p. 1313-52.
2. Chanock R.M., Kapikian A.Z., Mills J., Kim H.W., Parrott R.H. Influence of immunological factors in respiratory syncytial virus disease. Arch Environ Health. 21:1970;347-355.
3. Murphy B.R., Graham B.S., Prince G.A., Walsh E.E., Chanock R.M., Karzon D.T.et al. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol. 23:1986;1009-1014.
4. Crowe J.E. Jr., Bui P.T., London W.T., Davis A.R., Hung P.P., Chanock R.M.et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine. 12:1994;691-699.
5. Crowe J.E. Jr., Bui P.T., Davis A.R., Chanock R.M., Murphy B.R. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine. 12:1994;783-790.
6. Crowe J.E. Jr., Bui P.T., Siber G.R., Elkins W.R., Chanock R.M., Murphy B.R. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine. 13:1995;847-855.
7. Crowe J.E. Jr., Firestone C.Y., Whitehead S.S., Collins P.L., Murphy B.R. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes. 13:1996;269-273.
8. Karron R.A., Wright P.F., Crowe J.E. Jr., Clements M.L., Thompson J., Makhene M.et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus (RSV) vaccines in chimpanzees, adults, infants and children. J Infect Dis. 176:1997;1428-1436.
9. Friedewald W.T., Forsyth B.R., Smith C.B., Gharpure M.A., Chanock R.M. Low-temperature-grown RS virus in adult volunteers. JAMA. 203:1968;690-694.
10. Kim H.W., Arrobio J.O., Pyles G., Brandt C.D., Camargo E., Chanock R.M.et al. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. Pediatrics. 48:1971;745-755.
11. Connors M., Crowe J.E. Jr., Firestone C.-Y., Murphy B.R., Collins P.L. A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Virology. 208:1995;478-484.
12. Firestone C.Y., Whitehead S.S., Collins P.L., Murphy B.R., Crowe J.E. Jr. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology. 225:1996;419-422.
13. Juhasz K., Whitehead S.S., Bui P.T., Biggs J.M., Boulanger C.A., Collins P.L.et al. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J Virol. 71:1997;5814-5819.
14. Wyatt L.S., Moss B., Rozenblatt S. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology. 210:1995;202-205.
15. Collins P.L., Hill M.G., Camargo E., Grosfeld H., Chanock R.M., Murphy B.R. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci USA. 92:1995;11563-11567.
16. Whitehead S.S., Juhasz K., Firestone C.Y., Collins P.L., Murphy B.R. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol. 72:1998;4467-4471.
17. Garcin D., Pelet T., Calain P., Roux L., Curran J., Kolakofsky D. A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. EMBO J. 14:1995;6087-6094.
18. Crowe J.E. Jr., Collins P.L., London W.T., Chanock R.M., Murphy B.R. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine. 11:1993;1395-1404.
19. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine. 8:1990;497-502.
20. Murphy B.R., Park E.J., Gottlieb P., Subbarao K. An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine. 15:1997;1372-1378.
21. Subbarao E.K., Park E.J., Lawson C.M., Chen A.Y., Murphy B.R. Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine. J Virol. 69:1995;5969-5977.
22. Richman D.D., Murphy B.R. The association of the temperature-sensitive phenotype with viral attenuation in animals and humans: implications for the development and use of live virus vaccines. Rev Infect Dis. 1:1979;413-433.